EMEA-001397-PIP04-17-M01
Key facts
| Invented name |
|
| Active substance |
Ibrutinib
|
| Therapeutic area |
Immunology-Rheumatology-Transplantation
|
| Decision number |
P/0421/2019
|
| PIP number |
EMEA-001397-PIP04-17-M01
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of chronic Graft versus Host Disease (cGvHD)
|
| Route(s) of administration |
|
| Contact for public enquiries |
Janssen-Cilag International N.V.
Tel. +32 1 464 1125 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|